Theratechnologies Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Theratechnologies Inc Company

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Theratechnologies Inc Info



Ticker SymbolTHTX

Company nameTheratechnologies Inc

IPO dateDec 21, 1993

CEOMr. Paul Levesque

Number of employees94

Security typeOrdinary Share

Fiscal year-endDec 21

Address2015 Peel Street, 11th Floor

CityMONTREAL

Stock exchangeNASDAQ Capital Market Consolidated

CountryCanada

Postal codeH3A 1T8

Phone15143367800

Websitehttps://www.theratech.com/

Ticker SymbolTHTX

IPO dateDec 21, 1993

CEOMr. Paul Levesque

Company Executives of Theratechnologies Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Jocelyn Lafond

General Counsel, Company Secretary

--

-100.00%

Mr. Joseph P. Arena

Independent Director

--

Mr. John Leasure

Global Commercial Officer

--

-100.00%

Mr. Paul Levesque

President, Chief Executive Officer, Director

--

-100.00%

Mr. Frank A. Holler

Independent Non-Executive Chairman of the Board

--

-100.00%

Dr. Christian Marsolais, Ph.D.

Senior Vice President, Chief Medical Officer

--

-100.00%

Ms. Dale Maccandlish Weil

Independent Director

--

-100.00%

Mr. Andre Dupras

Vice President of Human Resources

--

Ms. Elina Tea

Independent Director

--

Mr. Andrew Thomas Molson

Independent Director

--

-100.00%

Name

Name/Position

Position

Shareholding

Change

Mr. Jocelyn Lafond

General Counsel, Company Secretary

--

-100.00%

Mr. Joseph P. Arena

Independent Director

--

Mr. John Leasure

Global Commercial Officer

--

-100.00%

Mr. Paul Levesque

President, Chief Executive Officer, Director

--

-100.00%

Mr. Frank A. Holler

Independent Non-Executive Chairman of the Board

--

-100.00%

Dr. Christian Marsolais, Ph.D.

Senior Vice President, Chief Medical Officer

--

-100.00%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

EGRIFTA

11.13M

62.78%

Trogarzo

6.60M

37.22%

By RegionUSD

Name

Revenue

Proportion

United States

17.73M

100.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

EGRIFTA

11.13M

62.78%

Trogarzo

6.60M

37.22%

Shareholding Stats

Updated: Fri, Oct 17

Shareholders

Shareholder Types

Shareholders

Proportion

Future Pak LLC

100.00%

Worth Venture Partners, LLC

1.16%

Trium Capital LLP

0.69%

National Bank of Canada

0.48%

Stonepine Capital Management, LLC

0.41%

Shareholders

Proportion

Future Pak LLC

100.00%

Worth Venture Partners, LLC

1.16%

Trium Capital LLP

0.69%

National Bank of Canada

0.48%

Stonepine Capital Management, LLC

0.41%

Shareholder Types

Shareholders

Proportion

Corporation

100.00%

Investment Advisor/Hedge Fund

2.82%

Investment Advisor

1.66%

Bank and Trust

0.48%

Research Firm

0.32%

Hedge Fund

0.16%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

75

2.49M

5.41%

-18.09M

2025Q2

91

22.32M

48.54%

-1.07M

2025Q1

91

22.45M

48.83%

-1.34M

2024Q4

86

23.57M

51.25%

-895.81K

2024Q3

83

24.25M

52.74%

-40.47K

2024Q2

85

24.07M

52.35%

-127.35K

2024Q1

90

23.97M

52.12%

-218.82K

2023Q4

90

24.01M

52.22%

+1.91M

2023Q3

92

7.44M

30.84%

-1.19M

2023Q2

93

7.55M

31.28%

-1.05M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Worth Venture Partners, LLC

533.40K

1.16%

-43.52K

-7.54%

Jun 30, 2025

National Bank of Canada

222.87K

0.48%

+25.80K

+13.09%

Jun 30, 2025

Stonepine Capital Management, LLC

189.05K

0.41%

+163.23K

+632.05%

Jun 30, 2025

SEB Investment Management AB

132.64K

0.29%

+132.64K

--

Jun 30, 2025

Dimensional Fund Advisors, L.P.

107.48K

0.23%

+77.64K

+260.12%

Jun 30, 2025

Harbour Investments, Inc

96.04K

0.21%

-67.00

-0.07%

Jun 30, 2025

Susquehanna International Group, LLP

80.67K

0.18%

+80.67K

--

Jun 30, 2025

Stifel, Nicolaus & Company, Incorporated

79.60K

0.17%

-500.00

-0.62%

Jun 30, 2025

Related ETFs



Updated: 18 hours ago

Name

Proportion

DFA Dimensional International Core Equity 2 ETF

0%

DFA Dimensional International Core Equity 2 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1

Date

Type

Ratio

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1

Jul 20, 2023

Merger

4→1